# Jonathan A. Ledermann

Source: https://onco.cc/people/jonathan-ledermann/  
OnCo record `jonathan-ledermann` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Led Study 19, the trial that first showed PARP inhibitor maintenance works in ovarian cancer.

## Summary

Jonathan Ledermann led Study 19, the randomised trial showing maintenance olaparib prolongs progression-free survival in platinum-sensitive relapsed ovarian cancer with the largest effect in BRCA-mutant disease, the proof of concept for every subsequent PARP inhibitor maintenance approval. He has led the ICON trials, chaired the Gynecologic Cancer InterGroup, and led ESMO-ESGO ovarian cancer guidelines.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: ovarian; parp; uk
- Role: Professor of Medical Oncology, UCL Cancer Institute; Consultant, UCLH
- Specialisms: Ovarian cancer; PARP inhibitors; Cooperative-group trials; Guidelines

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Ledermann%20JA%5BAuthor%5D%20ovarian%20olaparib

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [PARP inhibitors](https://onco.cc/technologies/parp-inhibitor/)
- targets: [BRCA1 / BRCA2 (HRD)](https://onco.cc/targets/brca/), [PARP](https://onco.cc/targets/parp/)
- drugs: [Olaparib](https://onco.cc/drugs/olaparib/)
- institutions: [University College London Hospitals / UCL Cancer Institute](https://onco.cc/institutions/uclh/)
- trials: [GOG-0218 & ICON7 (bevacizumab)](https://onco.cc/trials/gog-0218-icon7/)

---
JSON: https://onco.cc/api/v1/entities/jonathan-ledermann.json